CORRECTION  

出　　处：《Chinese Medical Journal》2009年第5期540-540,共1页中华医学杂志（英文版）

摘　　要：Background Galectin-3 is the most recently identified advanced glycosylation end products (AGEs) binding protein.This study aimed to investigate the effects of AGEs and rosiglitazone on the expression and secretion of galectin-3 incultured human renal mesangial cells (HRMCs).Methods HRMCs were incubated with different concentrations of AGE-bovine serum albumin (BSA) (0,50,100,200,and 400 mg/L) for different time (0,24,36,48,and 72 hours),and exposed to AGE-BSA in the presence of differentconcentrations of rosiglitazone (1,10,and 100 μmol/L).The mRNA and protein expression of galectin-3 in HRMCs wereanalyzed by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting.The culture medium ofHRMCs was collected and concentrated,and the content of galectin-3 in the medium was detected by Western blotting.Results Both RT-PCR and Western blotting revealed that AGE-BSA up-regulated the expression of galectin-3 inHRMCs in a concentration- (P <0.05) and time-dependent (P <0.05) manner compared with the control.Compared withthe control,AGE-BSA elevated the content of galectin-3 in the culture medium of HRMCs time- and concentration-dependently (P <0.05,respectively).Both protein and mRNA expression of galectin-3,and its content in the medium ofHRMCs exposed to different concentrations of rosiglitazone in the presence of AGE-BSA were increased compared withthose of cells exposed to AGE-BSA alone (P <0.05).Rosiglitazone increased the expression and secretion of galectin-3in a dose-dependent manner (P <0.05).Conclusions AGEs up-regulates the expression and secretion of galectin-3 in HRMCs.Rosiglitazone further enhancesthe upregulation of galectin-3 in HRMCs induced by AGEs,which suggests that rosiglitazone may play a role ofreno-protection via up-regulation of galectin-3.

分 类 号：R686[医药卫生—骨科学]